Istraživanja 3,4-diaril-1,2,5-oksadiazola i njihovih N-oksida: Potraga za boljim COX-2 inhibitorima by Mange Ram Yadav et al.
Discovery of two cyclooxygenase (COX) isoenzymes, a constitutive COX-1, serving
as homeostatic prostanoid producing agent, and COX-2, responsible for pro-inflamma-
tory prostanoid production, led to the development of new nonsteroidal anti-inflamma-
tory drugs (NSAIDs), selective COX-2 inhibitors, promising minimal NSAID-typical toxic-
ity with full anti-inflammatory efficacy. COX-2 inhibitors have been successful in treating
inflammatory diseases like acute pain, rheumatoid arthritis and osteoarthritis; a few of
them are also being studied for treating different types of cancer and Alzheimer’s disease
(1). Despite a few recent cautionary reports, the coxib treatment has a high degree of bene-
fit over risk, and strategies for using NSAIDs have been described by Antman et al. (2).
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Studies in 3,4-diaryl-1,2,5-oxadiazoles and their N-oxides:
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A series of 3,4-diaryl-1,2,5-oxadiazoles and 3,4-diaryl-
-1,2,5-oxadiazole N-oxides were prepared and evaluated
for COX-2 and COX-1 binding affinity in vitro and for anti-
-inflammatory activity by the rat paw edema method. p-
-Methoxy (p-OMe) substituted compounds 9, 21, 34, 41,
42 showed COX-2 enzyme inhibition higher than that
showed by compounds with other substituents. 3,4-Di(4-
-methoxyphenyl)-1,2,5-oxadiazole N-oxide (42) showed
COX-2 enzyme inhibition of 54% at 22 µmol L–1 and COX-1
enzyme inhibition of 44% at 88 mmol L–1 concentrations,
but showed very low in vivo anti-inflammatory activity.
Its deoxygenated derivative (21) showed lower COX-2 en-
zyme inhibition (26% at 22 µmol L–1) and higher COX-1
enzyme inhibition (53% at 88 µmol L–1) but, marked in
vivo anti-inflammatory activity (71% at 25 mg kg–1) vs. ce-
lecoxib (48% at 12.5 mg kg–1). Molecular modeling (dock-
ing) studies showed that the methoxy group is positioned
in the vicinity of COX-2 secondary pocket and it also par-
ticipates in hydrogen bonding interactions in the COX-2 ac-
tive site. These preliminary studies suggest that p-methoxy
(p-OMe) group in one of benzene rings may give poten-
tially active leads in this series of oxadiazole/N-oxides.
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A wide variety of carbocycles and heterocycles can serve as templates for COX-2 in-
hibitors, i.e., cyclopentene [SC-57666] (3) pyrazole [celecoxib (4), SC-58125 (5)], furan [ro-
fecoxib (6)], isoxazole [valdecoxib (7), paracoxib sodium (8)], and pyridine [etoricoxib
(9)]. In an ongoing research program in this department on COX-2 inhibitors with im-
proved biological profile, we synthesized (10) a series of 3,4-diaryl-1,2,5-oxadiazoles and
3,4-diaryl-1,2,5-oxadiazole N-oxides. The compounds are novel in that the vicinal diaryl
heterocyclic (five membered ring) pharmacophore of the coxibs has been incorporated
with the nitric oxide releasing group (1,2,5-oxadiazole N-oxide) into one single entity in
the compounds synthesized. In this paper, we report the synthesis, preliminary biologi-
cal evaluation and molecular docking studies of some of these oxadiazoles and their
N-oxides as selective COX-2 inhibitors.
1,2,5-oxadiazole N-oxides (furoxans) are reported (11) to be thiol dependent NO do-
nors, whose biological activity is produced by action on the soluble guanylate cyclase-
-cyclic guanosine monophosphate (sGC-cGMP) pathway. Furoxans are considered to
possess favorable bioactivity since they cause a slow release of NO resulting in longer
duration of action without development of tolerance. Granik and Grigor (12) proposed
the mechanism for the release of NO from 1,2,5-oxadiazole N-oxides. It is also reported
that release of NO from a nitric oxide donor drug produces beneficial effects such as re-
duction in blood pressure and prevention of atherosclerosis (11). NSAIDs possessing ni-
tric oxide releasing capabilities are considered to be more promising drugs than the
coxibs as these would be devoid of potential cardiovascular side effects associated with
coxibs (11). Recently, a report has been published discussing the synthesis of some mo-
nosubstituted 3,4-diaryl-1,2,5-oxadiazoles (11) and N-oxides (35) as selective COX-2 in-
hibitors, expecting them to be free from adverse cardiovascular effects (13), but we clai-
med synthesis of these compounds much earlier (10).
EXPERIMENTAL
The yields reported here are un-optimized. Melting points were determined using a
heating block-type melting point apparatus and are uncorrected. The IR spectra were re-
corded using the KBr disc method on an FT-IR model 8300 (Shimadzu, Japan). The 1H
NMR spectra on a 300 MHz spectrometer (Brucker, USA) were recorded in CDCl3 (che-
mical shifts in d ppm). Assignment of exchangeable protons (NH) was confirmed by the
D2O exchange. Selenium dioxide oxidations were carried out in an R-330F microwave
oven (Sharp, Carousel, Thailand). Final compounds were purified by passing through a
silica gel H (100-200 mesh, s. d. fine chemicals, India) purifying column using a mixture
of ethyl acetate and petroleum ether or chloroform alone as eluents.
Synthetic pathway is presented in Schemes 1 and 2, and physicochemical and spec-
tral data for the synthesized compounds are given in Tables I and II.
The starting compounds, 1,2-diaryl-1,2-ethanediones (2) (benzils), were prepared by
two routes. The first route involved benzoin condensation followed by oxidation (14, 15)
while the second involved Friedel-Crafts acylation followed by selenium dioxide oxida-
tion (16).
Syntheses of 1,2-diaryl-1,2-ethanedione dioximes (3). General procedure. – A mixture of
1,2-diaryl-1,2-ethanediones (2) (benzils) (10 mmol), hydroxylamine hydrochloride (60
14
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mmol) and pyridine (10 mL) was refluxed on an oil bath for 7 h. The reaction mixture
was poured onto crushed ice containing concentrated hydrochloric acid (10 mL). The
precipitate obtained was filtered, washed with cold water and dried. The crude materi-
als were used as such for the next step without further purification.
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X = H, 2-Cl, 4-Cl, 4-F, 4-Me, 4-OMe, NO2
Y = H, 4-Cl, 4-Br, 4-F, 4-Me, 4-OMe, 4-Sme, 4-SO2Me, 3,4-di-OMe
Reagents and conditions: a – AlCl3, CH2Cl2, 0–60 °C, 3–4 h; b – SeO2, Ac2O, reflux, 1–8 h; c – SeO2,
DMSO, microwave irradiation, 30–90 s; d – NH2OH ´ HCl, C6H5N, reflux, 7–8 h; e – (-CH2CO)2O,




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Syntheses of 3,4-diaryl-1,2,5-oxadiazoles (4–28). General procedure. – A mixture of 1,2-dia-
ryl-1,2-ethanedione dioximes (3) (4 mmol) and succinic anhydride (20 mmol) was heat-
ed at 180–185 °C for 10 min in an oil-bath. The molten product was cooled, suspended in
water and a sufficient quantity of sodium bicarbonate was added to neutralize the acid.
The resulting mixture was extracted with successive quantities of chloroform (3 ´ 25 mL).
The combined organic extract was washed with water (3 ´ 50 mL), dried and the solvent
was recovered. The product obtained was crystallized from methanol to yield the title
compounds.
Preparation of 3-(4-methylsulfonylphenyl)-4-(4-nitrophenyl)-1,2,5-oxadiazole (29). – To a
cooled solution of 28 (0.2 g, 0.64 mmol) in CH2Cl2 (20 mL), m-chloroperbenzoic acid
(m-CPBA) (1.0 g, 58 mmol, 55–75%) was added under stirring. Stirring was continued at
room temperature overnight. The reaction mixture was cooled to 0 °C and filtered at the
pump to remove benzoic acid. Aqueous sodium metabisulphite (20 mL, 10%, m/V) was
added to the filtrate and stirred for 15 min. The CH2Cl2 layer was separated and the
aqueous layer was extracted with CH2Cl2 (3 ´ 5 mL). The combined organic extract was
washed with aqueous sodium bicarbonate solution (5%, 2 ´ 10 mL) followed by water (3
´ 5 mL). The CH2Cl2 layer was dried over anhydrous sodium sulphate and recovered.
The resulting solid was crystallized from benzene to yield the title compound.
Syntheses of 3,4-diaryl-1,2,5-oxadiazole N-oxides (30–47). General procedure. – 1,2-Dia-
ryl-1,2-ethanedione dioxime (3) (0.5 g) was dissolved in methanol (10 mL). A freshly pre-
pared sodium hypochlorite solution (10 mL, 20%) was added dropwise to the above so-
lution at a temperature below 10 °C under stirring over a period of 30 min keeping the
temperature below 10 °C. After complete addition, the reaction mixture was further stir-
red for 1 h at a temperature below 10 °C and refrigerated overnight. The reaction mix-
ture was poured onto crushed ice and the solid obtained was filtered and dried. Crystal-
lization from methanol afforded the title compounds.
In vitro COX inhibition assay
The final compounds were evaluated for their ability to inhibit ovine COX-1 and
COX-2 enzymes [percent inhibition at a fixed molar concentration (mmol L–1)] (17). Inhi-
bition of the enzymes was determined with the colorimetric COX (ovine) inhibitor scre-
ening assay kit (Cayman Chemicals, USA) using ELISA reader following the procedure
described in the catalog. The experiments were performed in duplicates.
In vivo carrageenian induced rat paw edema assay
Anti-inflammatory activity was determined by the carrageenian-induced rat paw
edema method described by Winter et al. (18). Male Sprague-Dawley rats weighing 150
to 200 g (6–8 weeks old) were used in groups of six animals per group for the experi-
ments. The animals were housed in a room with temperature of 22 ± 2 °C under a 12 h
light/dark cycle. They were allowed free access to food and water ad libitum. The proto-
col for the animal experiments performed was approved by the IAEC (Institute Animal
Ethics Committee) registered under CPCSEA (Committee for the purpose of Control and
Supervision of Experiments on Animals) Govt. of India. Compounds were administered
orally as suspension in 1% carboxymethyl cellulose (CMC). Paw edema was induced by
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intradermal injection of 50 mL of 1% l-carrageenian (Sigma, USA) into the subplantar re-
gion of the right hind paw, after one hour of compound administration. The paw vol-
ume was measured immediately after injection and after 3 hours using a plethysmometer
(UGO-Basile, Italy). The control group received only the vehicle. Increase in paw vol-
ume was compared with that in the control group and percent inhibition was calculated
taking the values in the control group as 0% inhibition.
Molecular modeling (docking studies)
All the molecular modeling studies reported herein were performed on a Silicon
Graphics Fuel Workstation running on the IRIX 6.5 operating system using SYBYL 6.9
molecular modeling software from Tripos, Inc., USA (19) and GLIDE from Schrödinger
Inc., USA (20). All compounds used for docking were built from the fragments in the
SYBYL database. Each structure was fully geometry optimized using the standard Tri-
pos force field (21) with a distance-dependent dielectric function until a root mean square
deviation (rms) of 4.186 J Å–1 was achieved. Conformational search was carried out us-
ing MULTISEARCH option in SYBYL 6.9. The lowest energy conformer thus obtained
was further minimized using the Tripos force field and was subsequently used in dock-
ing. The COX-2 receptor structure (pdb code: 6COX) obtained from the Protein Data Bank
(USA) was refined to remove water molecules, adjust bond orders and formal charges
prior to docking. Docking was performed using GLIDE software according to their pre-
viously reported protocol (20).
RESULTS AND DISCUSSION
Chemistry
The general method employed for the preparation of 3,4-diaryl-1,2,5-oxadiazoles
(4–28) and 3,4-diaryl-1,2,5-oxadiazole N-oxides (30–47) and important intermediates 1–3
is illustrated in Scheme 1. Acid chlorides of phenylacetic acid and substituted phenyl-
acetic acids were obtained by refluxing the acid with thionyl chloride or phosphorous
trichloride. Excess of thionyl chloride or phosphorous trichloride was removed under
vacuum and the resulting acid chlorides were used as such in Friedel-Crafts acylation
reaction with benzene and monosubstituted benzenes to yield 1,2-diaryl-1-ethanones (1)
(16). IR spectra of these ethanones showed the presence of characteristic carbonyl stretch-
ing peaks at 1690–1665 cm–1. Their 1H NMR spectra showed characteristic signals for
-CH2- at about d 4.37 ppm.
1,2-Diaryl-1,2-ethanediones 2 (benzils) were synthesized by selenium dioxide (SeO2)
oxidation of 1 using AcOH/Ac2O as solvents at refluxing temperatures up to 8 h. The
reaction was completed under these conditions except for nitro substituted derivatives
of 1. Therefore, a new method was developed (16) for the oxidation of 1,2-diaryl-1-etha-
nones 1, which proved to be faster and more efficient. In this method, the reaction was
carried out in DMSO in a microwave oven for 30 s to afford the desired diones 2 in al-
most pure form. 1H NMR spectra of these diones 2 showed the absence of characteristic
signals for -CH2- at d 4.37 ppm. Some of benzils 2 were prepared by benzoin/cross ben-
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zoin condensation followed by oxidation, as per the reported procedures (14, 15). 1,2-Di-
phenyl-1,2-ethanedione (benzil), 1,2-di(4-methoxyphenyl)-1,2-ethanedione (anisil), 1-(2-
chlorophenyl)-2-(4-methoxyphenyl)-1,2-ethanedione and 1-(2-chlorophenyl)-2-(3,4-dime-
thoxyphenyl)-1,2-ethanedione were prepared by this method (14, 15).
Benzils 2 were oximated into the corresponding 1,2-diaryl-1,2-ethanedione dioxi-
mes 3 using the hydroxylamine hydrochloride/pyridine system at refluxing temperatu-
res. Most of the dioximes were isolated as solid compounds. Their TLC showed two
spots and IR spectra indicated the absence of keto stretching bands. Since there is a pos-
sibility of formation of syn and anti products, no efforts were made to isolate these geo-
metric isomers and the dioximes 3 were used as such for the next step.
Cyclization of 3 to 3,4-diaryl-1,2,5-oxadiazoles was attempted using different aci-
dic/basic dehydrating agents but could only be effected by heating with succinic anhy-
dride at 180–185 °C. Oxidation of 3 was carried out with aqueous sodium hypochlorite
solution (20%) to obtain 3,4-diaryl-1,2,5-oxadiazole N-oxides. It was observed that me-
thylsulfanyl (–SMe) also got oxidized to methylsulfonyl (–SO2Me) during sodium hypo-
chlorite treatment of compound 47. This was confirmed by the shift of methyl signal
from d 2.50 to d 3.11 ppm in its 1H NMR spectrum. Conversion of –SMe to –SO2Me was
also performed with m-CPBA either at 1,2-diaryl-1-ethanone 1 or at 3,4-diaryl-1,2,5-oxa-
diazole stages (Scheme 2). The elemental and spectral data of the synthesized compo-
unds are given in Tables I and II.
Biological and molecular modeling studies
All compounds described herein were evaluated in vitro for COX-2 binding affinity
at a concentration of 22 mmol L–1 by the colorimetric COX (ovine) inhibitor screening as-
say. Selected active compounds were also evaluated for COX-1 binding affinity at a higher
concentration (88 mmol L–1) (Table III). Compounds that showed promising COX-2 in-
hibitory activity were further screened for their anti-inflammatory activity (Table IV) in
vivo using the carrageenian induced rat paw edema method.
Amongst all the compounds, methoxy (-OMe) substituted compounds 9, 21, 34, 41,
42 showed COX-2 enzyme inhibition higher than that shown by compounds with other
substituents. 3,4-Di(4-methoxyphenyl)-1,2,5-oxadiazole N-oxide (42) showed COX-2 en-
zyme inhibition of 54% at 22 mmol L–1 and COX-1 enzyme inhibition of 44% at 88 mmol
L–1 concentration, but showed mild in vivo anti-inflammatory activity at a 25 mg kg–1
dose. However, its deoxygenated analog 21 showed lower COX-2 enzyme inhibition (26%
at 22 mmol L–1) and higher COX-1 enzyme inhibition (53% at 88 mmol L–1), but showed
stronger in vivo anti-inflammatory activity at a 25 mg kg–1 dose (71%) than standard
celecoxib at 12.5 mg kg–1 (48%). However, at the same dose level of 12.5 mg kg–1, it
showed much lower activity than (21%) celecoxib. This preliminary study suggests that
the methoxy (-OMe) group at 4-position of one of the phenyl rings may be a suitable
pharmacophore for COX-2 enzyme binding in this series of compounds. Replacement of
one of the -OMe groups of compound 21 by an electron withdrawing -NO2 group re-
sulted in a complete loss of COX-2 enzyme affinity. Compounds 11, 19, 20, 29 and 47
with the well known COX-2 enzyme pharmacophore (methylsulfonyl, -SO2Me) failed to
show COX-2 enzyme inhibition at a 22 mmol L–1 concentration, but compound 11 exhib-
ited in vivo anti-inflammatory activity at 25 mg kg–1 comparable to celecoxib at 12.5 mg
kg–1. Compound 21 was found to be the most active compound in the series.
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All the synthesized compounds were energy minimized and docked in the active
site of COX-2, but only a few binding interactions are discussed here. The binding inter-
action of 3,4-di(4-methoxyphenyl)-1,2,5-oxadiazole (21, 26% COX-2 inhibitory activity)
was studied within the COX-2 binding site by molecular docking studies. The para me-
thoxy group is oriented in the vicinity of COX-2 secondary pocket (Phe518, Arg513,
Gln192, Val523, Ser353) as shown in Fig. 1. The oxygen atom of the para substituted me-
thoxy group to the C-3 phenyl ring is hydrogen bonded with the backbone NH of Ile517
(distance = 4.1 Å). The oxygen atom of the other methoxy group that is para substituted
to C-4 phenyl ring also forms a hydrogen bond with OH of Tyr348 (distance = 4.9 Å). The
N2-atom of the central oxadiazole ring forms a favorable hydrogen bond with NH2 of
Arg120 (distance = 3.65 Å).
26
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Table III. In vitro COX-2 inhibition data for 3,4-diaryl-1,2,5-oxadiazoles





























a Compounds 5–7, 11–13, 16, 17, 20, 22, 24, 26–31, 33, 36, 39, 40, 43, 44, 46 and 47 were found to be inactive at
the concentration of 22 mmol L–1.
– Not evaluated.
b Experiments were performed in duplicate.
Binding mode of 3,4-di(4-methoxyphenyl)-1,2,5-oxadiazole N-oxide (42, 54% COX-2
inhibitory activity) was also examined (Fig. 2). As observed in other compounds, also
here the p-methoxy group is oriented towards the secondary pocket of the enzyme, which
is similar to the orientation of –SO2NH2 in celecoxib. The central oxygen atom of the
oxadiazole ring participates in hydrogen bond formation with NH2 of Arg120 (distance =
2.57 Å). Oxygen atom of N-oxide forms a favorable hydrogen bond with NH of Leu531.
The methoxy group substituted on the C-3 phenyl ring forms a hydrogen bond with
Tyr348 (distance = 4.8 Å). The methoxy group on the C-4 phenyl ring also participates in
the formation of the hydrogen bond with backbone NH of Ile517 (distance = 3.83 Å) and
NH of Gln192 (distance = 4.8 Å). Amongst all the compounds in the series, 42 had the
lowest intermolecular energy of –3.5 ´ 105 J mol–1, indicating its stability in the COX-2
active site.
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Fig. 1. Docking of compounds (ball and stick) in the active site of murine COX-2: a) 3,4-di(4-me-
thoxyphenyl)-1,2,5-oxadiazole (21) and b) 3,4-di(4-methoxyphenyl)-1,2,5-oxadiazole N-oxide (42).
Table IV. In vivo anti-inflammatory data for selected compounds
Compd. No. Dose (mg kg–1)
Paw volume (mL)
(% inhibition)a
Control 25 0.820 ± 0.02 (0)
11 25 0.28 ± 0.06 (53)
20 25 0.57 ± 0.10 (35)
21 25 0.16 ± 0.04 (71)
41 25 0.25 ± 0.03 (31)
42 25 0.04 ± 0.01 (5)
21 12.5 0.16 ± 0.04 (21)
Celecoxib 12.5 0.39 ± 0.05 (48)
a Mean ± SD, n = 6.
CONCLUSIONS
Docking studies of 3,4-diaryl-1,2,5-oxadiazoles and 3,4-diaryl-1,2,5-oxadiazole N-oxid-
es indicate a favorable orientation of the methoxy group in the COX-2 active site. Lower
binding energies also indicate the stability of 3,4-diaryl-1,2,5-oxadiazoles and their N-ox-
ides in the active site. This supports in vitro and in vivo anti-inflammatory data. These
preliminary studies suggest that the methoxy group may be acting as a pharmacophore
for the COX-2 enzyme binding site in series of 1,2,5-oxadiazoles and their N-oxides. Fur-
ther work in this direction is in progress.
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S A @ E T A K
Istra`ivanja 3,4-diaril-1,2,5-oksadiazola i njihovih N-oksida:
Potraga za boljim COX-2 inhibitorima
MANGE RAM YADAV, SHRIKANT T. SHIRUDE, DEVENDRA S. PUNTAMBEKAR, PINKAL J. PATEL,
HETAL B. PRAJAPATI, ARVIND PARMAR, R. BALARAMAN i RAJANI GIRIDHAR
Sintetizirana je serija 3,4-diaril-1,2,5-oksadiazola i 3,4-diaril-1,2,5-oksadiazol N-ok-
sida i ocijenjena njihova sposobnost vezivanja na COX-2 i COX-1 in vitro i protuupalno
djelovanje na edem {ape {takora. Spojevi sa p-metoksi (p-OMe) supstituentom 9, 21, 34,
41, 42 bolje su inhibirali COX-2 nego ostali spojevi. 3,4-Di(4-metoksifenil)-1,2,5-oksadia-
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zol N-oksid (42) inhibirao je COX-2 za 54% u koncentraciji od 22 mmol L–1, a COX-1 za
44% u koncentraciji 88 mmol L–1, ali je in vivo slabo djelovao protuupalno. Njegov deo-
ksigenirani derivat 21 pokazao je slabiju inhibiciju COX-2 enzima (26% u koncentraciji
22 mmol L–1) i ja~u inhibiciju COX-1 (71% u koncentraciji 25 mg kg–1), {to je bolje od
standarda celokoksiba (48% u koncentraciji 12,5 mg kg–1). Molekularno je modeliranje
pokazalo da je metoksi skupina smje{tena u blizini sekundarnog d`epa na enzimu COX-2
i da utje~e na vodikove veze interakcija na aktivnom mjestu COX-2. Ova preliminarna
istra`ivanja sugeriraju da bi se u seriji oksadiazol/N-oksida mogao na}i predvodni spoj
s p-metoksi skupinom na benzenskom prstenu.
Klju~ne rije~i: 1,2,5-oksadiazol, 1,2,5-oksadiazol N-oksid, COX-2 inhibitor
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